Heron Therapeutics (HRTX) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Heron Therapeutics (HRTX) over the last 5 years, with Q3 2025 value amounting to $7.22.
- Heron Therapeutics' Debt to Equity rose 126353.55% to $7.22 in Q3 2025 from the same period last year, while for Sep 2025 it was $7.22, marking a year-over-year increase of 126353.55%. This contributed to the annual value of -$0.74 for FY2024, which is 413.17% down from last year.
- Latest data reveals that Heron Therapeutics reported Debt to Equity of $7.22 as of Q3 2025, which was up 126353.55% from -$0.89 recorded in Q1 2025.
- Heron Therapeutics' 5-year Debt to Equity high stood at $7.22 for Q3 2025, and its period low was -$0.89 during Q1 2025.
- Its 3-year average for Debt to Equity is $0.25, with a median of -$0.72 in 2023.
- Data for Heron Therapeutics' Debt to Equity shows a peak YoY increase of 126353.55% (in 2025) and a maximum YoY decrease of 2239.13% (in 2025) over the last 5 years.
- Over the past 3 years, Heron Therapeutics' Debt to Equity (Quarter) stood at -$0.71 in 2023, then fell by 4.13% to -$0.74 in 2024, then skyrocketed by 1070.99% to $7.22 in 2025.
- Its Debt to Equity stands at $7.22 for Q3 2025, versus -$0.89 for Q1 2025 and -$0.74 for Q4 2024.